Please login to the form below

Not currently logged in
Email:
Password:

PharmaVentures increases its Asia-Pacific presence

Aki von Roy will be based in Auckland, New Zealand

edit-aki2Oxford, UK-headquartered advisory firm PharmaVentures has appointed Aki von Roy as an associate based in Auckland, New Zealand.

He has over 30 years experience in pharma and 16 years in biotech, and has been involved in 18 start up or merger ventures as director or investor.

Von Roy said: “I am delighted to join PharmaVentures, a firm with a proven track record in deal making.”

Formally he was the European president of Bristol-Myers Squibb (BMS), where he was responsible for $2.2bn in sales, more than 7,500 employees and around 40 subsidiaries. In 1997, he retired from BMS to establish RvR Associates, a private investment firm specialising in health and related matters.

Von Roy has also been chairman of private and publicly traded companies such as Genesis R&D, Phylogica, Vital Foods and Phytomedics and currently works as a venture partner at BioPacificVentures and an advisor to Direct Capital.

Fintan Walton, CEO of PharmaVentures, added: “Aki has a unique insight into innovative healthcare in the Asia-Pacific region and he will be a great benefit to both PharmaVentures and its clients.”

26th September 2014

From: Marketing

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics